Instilling confidence in ImmuneOnco's bispecific
The first data are dribbled out, but cross-trial comparisons look uninspiring.
Cardiff's questionable plan yields more questions
More data from onvansertib's phase 2 study fail to convince.
Celcuity's $5m pivot does the job
A Pfizer cast-off could become the company's first marketed drug.
